Evidence map›Paper›PMID 41983143›Full record

ReviewFrontiers in immunology2026

Focus on necroptosis: its role in the pathogenesis and therapeutic potential of osteoarthritis.

Yuhong Ouyang, Haiyang Liao, Wenjiao Kang, Fengyuan Li, Haili Shen

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuhong OuyangThe Second Clinical Medical College of Lanzhou University, Lanzhou, China.
Haiyang LiaoThe Second Clinical Medical College of Lanzhou University, Lanzhou, China.
Wenjiao KangThe Second Clinical Medical College of Lanzhou University, Lanzhou, China.
Fengyuan LiThe Second Clinical Medical College of Lanzhou University, Lanzhou, China.
Haili ShenDepartment of Rheumatology, Lanzhou University Second Hospital, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a prevalent degenerative joint disorder characterized by the progressive deterioration of joint structures. This deterioration results in pain and functional impairment and is a significant contributor to disability and economic strain. Necroptosis represents a crucial form of programmed cell death (PCD) that operates independently of caspases; it is governed by receptor-interacting protein kinase 1 (RIPK1), RIPK3, and mixed lineage kinase domain-like protein (MLKL). Necroptosis plays a pivotal role in various inflammatory, infectious, and degenerative pathologies. Recent research studies have highlighted the significant involvement of necroptosis in the advancement of OA. This article delineates the processes underlying the initiation and execution of necroptosis and explores its potential mechanisms within OA. It emphasizes the interplay between necroptosis and oxidative stress, inflammatory responses, extracellular matrix degradation, and cartilage repair and regeneration. Ultimately, this review assesses the existing evidence regarding the potential of targeting necroptosis as a therapeutic avenue for OA, positing that inhibition of the necroptosis pathway may emerge as a novel strategy to mitigate symptoms of OA and impede the progression of joint degeneration.

Indexed as

NecroptosisOsteoarthritisAnimalsHumansOxidative StressProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesSignal TransductionProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesMLKLnecroptosisosteoarthritis (OA)programmed cell death (PCD)RIPK1

Identifiers

PMID41983143
PMCPMC13071503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.